摘要
抗生素在临床上的广泛应用,导致耐药性问题日益严重。而肽类抗菌药作用机制独特,具有抗真菌、抗病毒、抗肿瘤活性,且不易产生耐药性,因此抗菌肽的研究已经日益深入。目前人们已从哺乳动物、植物、昆虫及微生物中分离得到抗菌肽,其中微生物来源的抗菌肽是抗菌肽家族的重要的成员。本文概述几种微生物来源的新抗菌肽,重点介绍目前已进入Ⅲ期临床试验的一种糖肽类抗菌肽Oritavancin。
Antimicrobial peptides （AMPs） have possessed unique mechanism of action, exhibited broad-spectrum activity against a wide range of microorganisms including Gram-positive and Gram-negative bacteria, protozoa, yeast, fungi, viruses and turnout cells. In addition, the resistant was not easy to produce. Recently, AMPs have been isolated from a wide variety of animals and plants as well as bacteria and fungi. The various novel antimicrobial peptides from microorganisms were described and paid attention to a semisynthetie glycopeptide antibiotic oritavancin （LY333328）, It is currently in phase Ⅲ clinical trials.
出处
《抗感染药学》
2006年第4期149-153,共5页
Anti-infection Pharmacy
